Clinicopathological evaluation of methotrexate-associated lymphoproliferative disorders with special focus on Epstein-Barr virus-positive mucocutaneous lesions
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Japanese Society for Lymphoreticular Tissue Research in Journal of Clinical and Experimental Hematopathology
- Vol. 60 (4) , 159-168
Abstract
Some patients diagnosed with methotrexate-associated lymphoproliferative disorder (MTX-LPD) develop spontaneous regression upon the discontinuation of MTX, whereas others require chemotherapy. The mechanisms underlying this differential response and the capacity to spontaneously regress are not clearly understood. We evaluated numerous clinicopathological features in 63 patients diagnosed with MTX-LPD, with a special focus on those with Epstein-Barr virus (EBV)-positive mucocutaneous lesions (EBVMCL). The diagnosis of EBVMCL included cases of both EBV-positive mucocutaneous ulcers (EBVMCU) and diffuse gingival swelling associated with proliferation of EBV-positive large B-cells. Of the four subgroups of MTX-LPD, one-year treatment-free survival (TFS) after the discontinuation of MTX was achieved among those with EBVMCL (100%), diffuse large B-cell lymphoma (57%), Hodgkin-like lesions (60%), or classical Hodgkin lymphoma (29%); a significant difference in TFS was observed when comparing the responses of patients with EBVMCL to the those diagnosed with other subtypes. Multivariate analysis revealed predictive factors for prolonged TFS that included EBV-positive lesions and comparatively low levels of serum LDH. Taken together, our study suggests that a diagnosis of EBVMCL is related to the overall clinical outcome after the discontinuation of MTX.Keywords
This publication has 32 references indexed in Scilit:
- Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein–Barr virus, and clonality are important predictors of disease progression and regressionEuropean Journal of Haematology, 2013
- Epstein-Barr virus–positive mucocutaneous ulcer of the oral cavity: the importance of having a detailed clinical history to reach a correct diagnosisOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012
- EBV Positive Mucocutaneous Ulcer—A Study of 26 Cases Associated With Various Sources of ImmunosuppressionAmerican Journal of Surgical Pathology, 2010
- Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese casesPathology - Research and Practice, 2006
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- Biology and Treatment of Epstein-Barr Virus–Associated Non-Hodgkin LymphomasHematology-American Society Hematology Education Program, 2005
- Reactivation of Latent Epstein-Barr Virus by Methotrexate: A Potential Contributor to Methotrexate-Associated LymphomasJNCI: Journal of the National Cancer Institute, 2004
- Methotrexate markedly reduces the expression of vascular E‐selectin, cutaneous lymphocyte‐associated antigen and the numbers of mononuclear leucocytes in psoriatic skinExperimental Dermatology, 2004
- Lymphoma subtypes in patients with rheumatoid arthritis: Increased proportion of diffuse large B cell lymphomaArthritis & Rheumatism, 2003
- Hodgkin's Disease and Lymphoproliferations Resembling Hodgkin's Disease in Patients Receiving Long-Term Low-Dose Methotrexate TherapyAmerican Journal of Surgical Pathology, 1996